EMA to drug de­vel­op­ers on AI: Car­ry out thor­ough risk as­sess­ments

The EMA is urg­ing drug de­vel­op­ers to ap­pro­pri­ate­ly as­sess the risk of us­ing ar­ti­fi­cial in­tel­li­gence or ma­chine learn­ing in the drug de­vel­op­ment process and to seek reg­u­la­to­ry in­ter­ac­tions ear­ly on, in a new re­flec­tion pa­per ad­dress­ing the grow­ing use of AI/ML in drug de­vel­op­ment.

In a 17-page pa­per pub­lished Ju­ly 10, EMA lays out the role of AI and ML through­out the life­cy­cle of med­i­c­i­nal prod­ucts. Fur­ther reg­u­la­to­ry guid­ance on risk man­age­ment in drug de­vel­op­ment will be forth­com­ing, the agency says.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER